Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced the acceptance of two CHM 1101 (CLTX CAR T) abstract presentations at the 26th annual scientific meeting of the Society for Neuro-Oncology.
The company said the clinical evaluation of the initial dose cohort in the phase 1 clinical trial for CHM 1101 (CLTX CAR T) will be presented on 19 November. This abstract presentation will provide new information on the safety, efficacy, and bioactivity of CHM 1101.
According to CEO and managing director Jennifer Chow, “These data are critical to advancing our clinical development program. At the low dose level that patients in this cohort received, we are focused on being able to establish safety and bioactivity in patients.
"Once we are able to further characterize the safety and bioactivity of CHM 1101, we will be able to move forward to focus on our exploration of efficacy at the higher dose levels in the trial with dual routes of administration.”
Abstract EXTH-10, which will also be presented on 19 November, will provide further insight into the mechanism by which CHM 1101 (CLTX CAR T) recognises glioblastoma tumour cells.